How a Specialty Pharmacy Billing Company Protects Accuracy When Biosimilars Enter the Picture

Biosimilars were introduced with the intention of making life easier for specialty pharmacy. They generally act as more economical alternatives to expensive biologic medications, and truth be told insurance payers love them. Simply put, scrutiny from payers decreases naturally, and chances of claim acceptance rise.

However, billing for biosimilar medications is a whole different story and a complex one. Even the smallest discrepancy between what the prescription said and what was delivered can cause direct claim denials. And this is where an expert specialty pharmacy billing company earns their place.

Understanding Biosimilars and Substitution

A biosimilar is typically a biologic medicine, that is almost same as any FDA-approved reference item. Typically there are no differences between the reference product and the biosimilar as far as clinical safety and effectiveness is concerned. However, they are not exact copies or biologics like generics are, and small variations can exist.

However, when it comes to billing, the difference is usually immense.

• An interchangeable biosimilar is one the FDA has cleared for swapping with the reference product right at the pharmacy counter. The pharmacist will not be required to call the prescriber first, though state law still has the final say.

• A biosimilar without that label is a different story. In most cases, the pharmacy needs a documented acceptance from the prescriber before the switch happens.

• Substitution rules also vary from one state to another. Each state has their own measure on how substitutions must be managed.

Where Billing Accuracy Breaks Down

When it comes to biosimilar billing, errors do not come from a single big mistake. Usually smaller discrepancies add up to create significant billing issues.

One of the most common errors is NDC mismatch. Every specialty medication comes with their own National Drug Code (NDC), and biosimilars are no different. Now if the claim wrongly uses the reference product's NDC, meaning the one based on which the biosimilar was substituted, instead of the NDC of the specific biosimilar, or vice versa, then chances of claim denial increase.

Biologics usually come in prefilled vials and so do biosimilars. However, the billing unit measures, package sizes, and supply per day can vary significantly between the reference biologic and its biosimilar. In such a case, application of an inaccurate unit or measure can lead to significant claim discrepancies.

The formulary preferences towards these biosimilars tend to differ between pharmacy benefit managers and payers. Simply put, one payer of PBM may accept one biosimilar during a quarter, but their preference towards it may change during the next. This adds another layer of administrative complexity for billers.

Often practices think switching to a biosimilar will carry over an existing prior authorization for a biologic drug. However, that is not the case, and most of the time insurance providers require practices to seek new authorization for the biosimilar separately. Additionally, they may require evidence of step therapy and even documented reason for making the switch.

To inform the payer that the substitution was allowed or requested, billers must use the Dispense as Written (DAW) codes accurately. Even the slightest discrepancy here can lead to direct claim denials.

Many specialty drugs can be billed under either benefit. Biosimilars add another layer, since coverage rules and billing codes, such as HCPCS Q-codes on the medical side, may differ from the reference product.

The Financial Impact of Getting It Wrong

When it comes to the cost of these errors, it undeniably goes beyond a single claim denial. Specialty medications generally come with huge price tags, so even a small percentage of claim denials can cause significant revenue loss. Not only that, the appealing and making necessary reworks can exhaust double the resources and time. Accounts receivable ages, and cash flow gets slower.

Apart from these obvious impacts, such claim issues can trigger audits. PBMs and payers very regularly review specialty pharmacy dispensing records, and if there are any discrepancy between the documentation and the dispensed biosimilar, then chances of facing a clawback rises, even if the drug was delivered way back. These are the kind of gap an expert specialty pharmacy billing company was built to close.

How an Expert Specialty Pharmacy Billing Company Helps

Accurate Claim Setup from the Start

An experienced billing team understands the importance of submitting clean claims for first-pass acceptance. This is why they thoroughly review all codes mentioned and units before submitting the claim. This helps with catching any discrepancy early, further reducing the chances of claim denial.

Early Benefit Verification

Before delivering the biosimilar, an expert specialty pharmacy billing company takes the time to verify eligibility properly. The team checks whether the insurer prefers a particular product first. They also find out the benefit under which the biosimilar will be billed and whether prior authorization is needed. Catching these details early means fewer surprises at the claim stage, and the patient's therapy does not get held up.

Payer and PBM Policy Tracking

Payer policies keep changing and keeping up with them can become a full-time task. An expert specialty pharmacy billing company stays current with all these updates through regular training and education. This enables them to adjust claims as per payer-specific policies before claim submission, further increasing the first-pass claim acceptance rate.

Documentation That Holds Up in an Audit

Accurate documentation is literally the biggest foundation for successful claim processing. Seasoned billing teams understand that, and ensure claims are supported with all necessary documentation, including the original prescription, any prescriber communication about the switch, the substitution rationale, and the state notification where required.

Denial Management with a Purpose

Even with strong processes in place, denials still happen. However, this is where an expert specialty pharmacy billing company earns in place in the way they handle denials. Doing needed reworks and filing an appeal is just a basic part of the job. The team also thoroughly checks why the denial happened and corrects the problem at its source. That way, the same mistake does not keep happening repeatedly.

Reconciliation and Payment Posting

Matching the 835 remittance advice against the submitted claim can be considered redundant, but when it comes to biosimilar billing, this is necessary. The reason is, this is where most underpayments tend to hide. An expert specialty pharmacy billing company understands that, and they make sure to review each payment against the expected one. Such careful consideration helps with proper revenue management.

Reporting and Visibility

An expert specialty pharmacy billing company also ensures to offer clear reporting. Simply put, they will offer valuable insights on denial trends, information on outstanding balances, and the reimbursement performance of biosimilar products. This sort of thorough information helps with making smarter decisions.

Final Thoughts

The use of biosimilars is an essential element in the future of specialty healthcare; biosimilars will help reduce the cost of drugs and increase patient access to medications. However, the use of them will also add significantly to the complexity of how pharmacies process claims. Working with an experienced specialty pharmacy billing company gives pharmacies a way to handle that complexity with confidence.